Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CHRS 
Coherus BioSciences Inc (CHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: CHRS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.68
1 Year Target Price $4.68
| 3 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.15M USD | Price to earnings Ratio 1.69 | 1Y Target Price 4.68 |
Price to earnings Ratio 1.69 | 1Y Target Price 4.68 | ||
Volume (30-day avg) 7 | Beta 0.88 | 52 Weeks Range 0.66 - 2.43 | Updated Date 06/30/2025 |
52 Weeks Range 0.66 - 2.43 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -48.09% | Operating Margin (TTM) -597.91% |
Management Effectiveness
Return on Assets (TTM) -9.1% | Return on Equity (TTM) -1657.06% |
Valuation
Trailing PE 1.69 | Forward PE 41.15 | Enterprise Value 273306624 | Price to Sales(TTM) 0.32 |
Enterprise Value 273306624 | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 1 | Enterprise Value to EBITDA 3.41 | Shares Outstanding 115933000 | Shares Floating 110892497 |
Shares Outstanding 115933000 | Shares Floating 110892497 | ||
Percent Insiders 6.54 | Percent Institutions 54.49 |
Analyst Ratings
Rating 3 | Target Price 4.68 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Coherus BioSciences Inc
Company Overview
History and Background
Coherus BioSciences Inc. was founded in 2010. It's a commercial-stage biopharmaceutical company focused on developing and commercializing biosimilar products and innovative immuno-oncology therapeutics. Key milestones include the approvals and launches of biosimilars for Neulasta and Humira.
Core Business Areas
- Biosimilars: Development and commercialization of biosimilars referencing originator biologics, offering more affordable treatment options.
- Immuno-oncology: Development of innovative immuno-oncology therapeutics targeting the tumor microenvironment.
Leadership and Structure
The leadership team includes Denny Lanfear (CEO), and McDavid Stilwell (CFO). The company operates with a functional organizational structure focused on R&D, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Udenyca (pegfilgrastim-cbqv): A biosimilar to Neulasta, used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Udenyca holds a significant share of the pegfilgrastim market, facing competition from Amgen (Neulasta), Mylan (Fulphila), and others. The revenue from Udenyca has been a major source of income for Coherus.
- Yusimry (adalimumab-aqvh): A biosimilar to Humira, used to treat autoimmune diseases. It launched on July 1, 2023. Key competitors include Amjevita (Amgen), Cyltezo (Boehringer Ingelheim) and other Humira biosimilars. As a more recent launch, market share data is still evolving.
- Loqtorzi (toripalimab-tpzi): An anti-PD-1 monoclonal antibody approved by FDA in combination with gemcitabine and cisplatin for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). Key competitors are Keytruda and Opdivo.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Biosimilars are gaining acceptance as cost-effective alternatives to originator biologics. Immuno-oncology is a rapidly growing field with significant unmet medical needs.
Positioning
Coherus BioSciences Inc is positioned as a biosimilar company expanding into immuno-oncology. Its competitive advantages include its experience in biosimilar development and commercialization, as well as its focus on innovative immuno-oncology therapeutics.
Total Addressable Market (TAM)
The biosimilars market is projected to reach billions of dollars, and the immuno-oncology market is substantially larger. Coherus is positioned to capture a share of both markets, particularly as biosimilar adoption increases and its immuno-oncology pipeline advances.
Upturn SWOT Analysis
Strengths
- Biosimilar expertise
- Established commercial infrastructure
- Expanding immuno-oncology pipeline
- FDA approved products
- Partnerships for development and commercialization
Weaknesses
- Reliance on biosimilar market dynamics
- Competition from larger pharmaceutical companies
- R&D risks associated with drug development
- Debt levels
- Reliance on single product revenue
Opportunities
- Expanding biosimilar market
- Advancements in immuno-oncology
- Partnerships and collaborations
- New product development
- Geographic expansion
Threats
- Increased competition in the biosimilar market
- Pricing pressures
- Regulatory changes
- Patent challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AMGN
- ABBV
- BMY
- MRK
- PFE
Competitive Landscape
Coherus faces strong competition from larger pharmaceutical companies with greater resources and established market positions. Its advantages lie in its biosimilar expertise and targeted immuno-oncology approach.
Major Acquisitions
Surface Oncology
- Year: 2023
- Acquisition Price (USD millions): 65
- Strategic Rationale: Surface Oncology brought novel oncology assets targeting the tumor microenvironment. Acquisition allows expansion into immuno-oncology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by biosimilar launches and market penetration.
Future Projections: Future growth is expected to be driven by the success of its immuno-oncology pipeline and continued expansion in the biosimilar market. Analyst estimates vary, reflecting uncertainty in drug development and market dynamics.
Recent Initiatives: Recent initiatives include launching Yusimry, advancing its immuno-oncology pipeline, and seeking partnerships to expand its product portfolio.
Summary
Coherus BioSciences is a commercial-stage biopharmaceutical company showing promise with its biosimilar products like Udenyca and Yusimry, complemented by its immuno-oncology development. The company faces strong competition, particularly in the biosimilar market, and successful launch of newer biosimilars and the advancement of its immuno-oncology pipeline are key for future growth. Financial performance and market capitalization have been fluctuating and the company needs to handle its cash flow and debt load. They need to look out for pricing pressures and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Coherus BioSciences Inc. Investor Relations
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coherus BioSciences Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-06 | Chairman, President & CEO Mr. Dennis M. Lanfear | ||
Sector Healthcare | Industry Biotechnology | Full time employees 221 | Website https://www.coherus.com |
Full time employees 221 | Website https://www.coherus.com | ||
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.